Table 1:

Baseline characteristics of treated subjects

Variable	Overall (N = 111)	IV tPA (N = 30)	No IV tPA (N = 81)	P Value
Age, y (mean ± SD)	66.2 ± 17.0	65.4 ± 13.5	66.5 ± 18.2	.772^†
Female, %	56.8%	56.7%	56.8%	>.99^‡
Baseline NIHSSS^* (mean ± SD)	19.0 ± 6.3	19.6 ± 4.3	18.8 ± 6.9	.565^†
Hours to device treatment, median (range)	4.2 (1.3–17.3)	3.6 (2.1–7.0)	4.4 (1.3–17.3)	.072^§
Procedure length (h), median (range)	1.6 (0.5–5.8)	1.6 (0.6–3.3)	1.7 (0.5–5.8)	.353^§
No. of passes (mean ± SD)	2.8 ± 1.6	2.7 ± 1.7	2.8 ± 1.6	.460^§
IV tPA, N (%)	30 (27.0)	30 (100)	0 (0)	–
IA tPA postretriever, N (%)	43 (38.7)	13 (43.3)	30 (37.0)	.661^‡
Vascular occlusion location, N (%)				.296^¶
ICA	1 (0.9)	1 (3.3)	0 (0)
ICA-T	32 (28.8)	10 (33.3)	22 (27.2)
MCA	68 (61.3)	18 (60.0)	50 (62.0)
Vertebral alone	0	0	0
Vertebral + basilar, basilar	9 (8.1)	1 (3.3)	8 (9.9)
P1	1 (0.9)	0 (0)	1 (1.2)

Note:—IV tPA indicates intravenous tissue-type plasminogen activator; NIHSSS, National Institutes of Health Stroke Scale score; IA, intraarterial; ICA, intracranial carotid artery; ICA-T, ICA terminal bifurcation; MCA, middle cerebral artery.
* One posterior circulation (distal basilar artery occlusion) patient was enrolled against protocol with a baseline NIHSS score of 4. No other patients had a baseline NIHSS score below the required protocol score of 8. Procedure length was the time from groin puncture to final angiogram.
† t Test.
‡ Fisher exact test.
§ Wilcoxon rank-sum test.
¶ Likelihood ratio χ² test.